UNSPSC 51263169: Metoprolol tartrate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C15H25NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5S57Y3A5L, chemically known as 2-propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)- but more generally known as metoprolol tartrate, which bears US NIH Compound Identifier 4171. European Medicines Agency schedules Metoprolol tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03275MIG.

UNSPSC 51263169 Metoprolol tartrate is a Commodity code for a specific cardiac medication, but the only recent state and local opportunity tagged under it involves procurement of naloxone and drug deactivation systems for opioid-overdose response and harm reduction, which falls outside the pharmaceutical-formulary scope the code name suggests. The mismatch indicates that either the tagging is erroneous or the code is being applied to broader emergency-response medical supplies beyond its nominal pharmaceutical scope. State and local procurement activity under this code's nominal description—metoprolol tartrate tablets or solutions for formulary stocking by health departments, county clinics, or jail health services—is not represented in the recent opportunity record.

Seminole County, Florida posted the only visible recent opportunity, an IFB (Invitation for Bid) released June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with a response deadline of July 26, 2023, with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The contract terms include a two-year initial period with one-year renewal option, fixed-fee pricing, drug-free workplace certification, E-Verify compliance, and potential FEMA funding subject to federal environmental regulations. Because the recent-opportunities record shows no other jurisdictions or metoprolol tartrate solicitations, the activity profile under this code remains unclear; firms evaluating pursuit should verify whether the naloxone procurement represents a systematic tagging error or a shift in how the jurisdiction classifies emergency pharmaceutical and medical-device acquisitions.